Show simple item record

dc.contributor.authorWorld Health Organization
dc.description.abstractCurrently, there are no therapeutic agents licensed and available for the treatment of COVID 19. On the 27th of January, WHO convened a meeting of experts to examine the available evidence and prioritize promising therapeutic agents for further evaluation in the ongoing outbreak. The expert panel recommended the direct-acting antiviral agent, Remdesivir, and the protease inhibitor, Lopinavir/ritonavir for evaluation in randomized clinical trials. At the time, there was insufficient evidence to support chloroquine’s further investigation. However, chloroquine has received significant attention in countries as a potentially useful prophylactic and curative agent, prompting the need to examine emerging evidence to inform a decision on its potential role. At the time of convening this meeting, about 500 clinical trials were ongoing in China, with at least 13 evaluating chloroquine’s efficacy. This expert consultation convened clinical care partners and experts in the field of randomized controlled trials (RCTs), preclinical studies, and chloroquine pharmacology for evaluating newly available evidence.en_US
dc.titleCOVID-1. Informal consultation on the potential role of chloroquine in the clinical management of COVID 19 infection, draft 13 March 2020en_US
eihealth.countryGlobal (WHO/OMS)en_US
eihealth.categoryCandidate therapeutics RDen_US
eihealth.typeWHO / PAHO Guidanceen_US
eihealth.maincategorySlow Spread / Reducir la Dispersiónen_US

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record